Kawasaki Disease Shock Syndrome

1. DEFINITION

Kawasaki Disease Shock Syndrome (KDSS) is a severe, life-threatening manifestation of Kawasaki Disease (KD) characterized by the presence of standard KD criteria along with hemodynamic instability. Specifically defined by:
- Sustained decrease in systolic blood pressure below the 5th percentile for age and sex, OR
- Clinical signs of poor perfusion (tachycardia, prolonged capillary refill time >2 seconds, cold extremities, weak pulses, oliguria, or altered sensorium) requiring volume expansion or vasoactive/inotropic support.

KDSS represents the extreme end of the inflammatory spectrum in KD. The profound hypotension and shock are multifactorial:

Profound Capillary Leak: Widespread endothelial dysfunction and severe systemic vasculitis lead to fluid extravasation into the extravascular space.
Myocardial Dysfunction: Acute severe myocarditis causing depressed left ventricular systolic function and low cardiac output.
Cytokine Storm: Massive release of pro-inflammatory cytokines (Interleukin-6, Interleukin-10, Tumor Necrosis Factor-alpha, and Interferon-gamma), leading to profound vasodilation and distributive shock.

Patients with KDSS often present with distinct phenotypic differences compared to classic KD:

Demographics: Tends to affect older children and females more frequently.
Hemodynamic: Distributive, cardiogenic, or mixed shock presentation.
Gastrointestinal: High frequency of severe GI symptoms (vomiting, abdominal pain, diarrhea, hepatitis) resembling an acute abdomen.
Neurological: Higher incidence of aseptic meningitis and altered sensorium.
Respiratory: Pleural effusions and respiratory distress are more common.

Hematology: Pronounced neutrophilia with severe left shift, marked anemia. Thrombocytopenia is notably more common in KDSS (consumptive coagulopathy) compared to the thrombocytosis seen in classic KD.
Inflammatory Markers: Exceptionally high C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Procalcitonin.
Biochemistry: Hypoalbuminemia (severe capillary leak), elevated transaminases, hyponatremia, and elevated creatinine (pre-renal acute kidney injury).
Cardiac Biomarkers: Elevated Troponin I/T and markedly elevated BNP or NT-proBNP reflecting myocardial injury and strain.
Echocardiography:
- Critical for evaluating LV/RV ejection fraction and fractional shortening (myocardial dysfunction).
- Assessment of mitral/aortic regurgitation.
- Evaluation for Coronary Artery Abnormalities (CAA), which occur at a significantly higher rate in KDSS.

Requires intensive care unit (ICU) admission and a dual approach addressing both hemodynamic collapse and severe systemic inflammation.

Fluid Resuscitation: Cautious administration of isotonic crystalloids (10-20 ml/kg aliquots) monitoring closely for fluid overload due to underlying myocarditis/depressed LV function.
Inotropes/Vasopressors: Epinephrine or Norepinephrine are often required for vasoplegia. Milrinone is utilized if cardiogenic shock/myocardial dysfunction predominates (improves contractility and reduces afterload).

Intravenous Immunoglobulin (IVIG): 2 g/kg as a single infusion over 10-12 hours. (Patients with KDSS have a much higher rate of IVIG resistance).
Aspirin: Moderate to high dose (30-50 mg/kg/day) until afebrile for 48 hours, then step down to antiplatelet dose (3-5 mg/kg/day).
Corticosteroids: Strongly recommended as primary adjunctive therapy in KDSS due to high risk of IVIG resistance. Intravenous Methylprednisolone (IVMP) pulse (30 mg/kg/day for 1-3 days) followed by an oral taper.
Biological Agents: Infliximab (TNF-alpha inhibitor, 5 mg/kg single dose) or Anakinra (IL-1 receptor antagonist) should be considered early in refractory cases.

Coronary Artery Abnormalities (CAA): KDSS patients have a dramatically increased risk of developing giant coronary aneurysms compared to classic KD patients.
IVIG Resistance: Occurs in up to 40-60% of KDSS cases, necessitating early aggressive escalation of immunosuppression.
Mortality: Higher than classic KD, primarily due to catastrophic cardiac failure, arrhythmias, or ischemic events.